Indofarma's Sales Increased by 69% in 2021

Reza Pahlevi 22/04/2022 16:40 WIB

Bagikan URL has been copied

Memuat...

Indofarma's sales reached Rp2.9 trillion in 2021, a 69% increase from Rp1.72 trillion in 2020.

Indofarma Net Revenue and Profit/Loss (2017-2021)

A Font Kecil
A Font Sedang
A Font Besar

Access single data

Indofarma's Sales Increased by 69% in 2021

Want to get more access to Data Stories with a more affordable price? Subscribe.

By subscribing, you join us in presenting quality data.

Get:

Premium Data Stories access
Comfortable reading without ads
Download data in XLS, PDF, and image format
Access to data source information

Basic

~~Rp100.000~~

Rp50.000/month

Professional

~~Rp100.000~~

Rp150.000/month

Institutional For organizations

We accept the following payments:

Some payment methods are still in the process of being activated.

Indofarma Net Revenue and Profit/Loss (2017-2021)

Download

Source

A Small
A Medium
A Bigger

The state-owned pharmaceutical company, PT Indofarma Tbk, recorded sales of Rp2.9 trillion (approximately US$197 million) in 2021. This represents a 69% increase from Rp1.72 trillion (approximately US$117 million) in 2020.

Indofarma's sales were dominated by drug sales, reaching Rp2.1 trillion (approximately US$143 million). Meanwhile, sales of medical devices and other products totaled Rp802.1 billion (approximately US$54 million).

Despite the increase in sales, Indofarma recorded a net loss of Rp37.58 billion (approximately US$2.5 million). This is in stark contrast to the Rp27.58 million (approximately US$1,800) profit achieved in 2020.

One reason for this loss was the 86% increase in cost of goods sold, which swelled to Rp2.45 trillion (approximately US$167 million). In 2020, the cost of goods sold was Rp1.31 trillion (approximately US$89 million).

Indofarma is part of the state-owned pharmaceutical holding company, which also includes PT Biofarma (Persero) and PT Kimia Farma Tbk. Biofarma acts as the parent holding company.

Editor : Annissa Mutia

"Disclosure: This is an AI-generated translation of the original article. We strive for accuracy, but please note that automated translations may contain errors or slight inconsistencies."